Latest News about ESPR
Recent news which mentions ESPR
First Republic Bank sinks on possible sale reports, and Credit Suisse’s stock boosted by central bank borrowing
March 16, 2023
From MarketWatch
From InvestorPlace
LivePerson, Amyris And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 16, 2023
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 14, 2023
From Benzinga
From Benzinga
From Benzinga
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
March 06, 2023
From Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 06, 2023
From Benzinga
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
From Benzinga
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
March 06, 2023
From Benzinga
From MarketWatch
Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors
March 06, 2023
Tickers
ESPR
From Benzinga
Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
March 06, 2023
From Benzinga
Looking Into Esperion Therapeutics's Return On Capital Employed
February 22, 2023
Tickers
ESPR
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
From Benzinga
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
December 07, 2022
Tickers
ESPR
From Benzinga
Esperion Therapeutics's Return On Capital Employed Insights
November 09, 2022
Tickers
ESPR
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
August 03, 2022
From Benzinga
From Benzinga
Esperion Therapeutics (ESPR) Q2 2022 Earnings Call Transcript
August 02, 2022
Tickers
ESPR
From Motley Fool
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|